Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ACC In Brief

This article was originally published in The Tan Sheet

Executive Summary

PREVU(x) POC in action: A skin sterol testing method was successfully employed to detect subclinical vascular disease, according to an 81-subject study presented by Wendy Tzou, MD, University of Wisconsin Medical School, et al., at the American College of Cardiology Annual Scientific Session in Orlando, Fla. March 7. Carotid intima media thickness, "a well-established marker of atherosclerosis," was significantly higher among patients in the population exhibiting the highest skin sterol measurement using PREVU(x) Point of Care test, according to the test's marketer, Toronto-based IMI. The data "confirm that skin sterol testing has the ability to help identify patients at risk of heart disease non-invasively and cost effectively," CEO Brent Norton asserts. IMI signed a marketing agreement with McNeil last year and is developing an OTC version of the product (1"The Tan Sheet" June 7, 2004, p. 10)...

Related Content

Topics

UsernamePublicRestriction

Register

PS097943

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel